Fibulin-5 is down-regulated in urothelial carcinoma of bladder and inhibits growth and invasion of human bladder cancer cell line 5637

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 4, 2011, Pages 430-435

  Hu, Zheng ^a,b   Ai, Qing ^a,b   Xu, Hua ^b   Ma, Xin ^a   Li, Hong zhao ^a   Shi, Tao ping ^b   Wang, Chao ^b   Gong, Dao jing ^b   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell proliferation; Fibulin 5; Genes, tumor suppressor; Neoplasm invasiveness; Urinary bladder; Urothelial carcinoma

Indexed keywords

COMPLEMENTARY DNA; FIBULIN 5; GREEN FLUORESCENT PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BLADDER UROTHELIAL CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GROWTH CURVE; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO GENE TRANSFER; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

AGED; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 79959896489     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.06.004     Document Type: Article

References (22)

1. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
3. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
4. Strefford J.C., Lillington D.M., Steggall M., et al. Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2002, 135:139-146.
5. Timpl R., Sasaki T., Kostka G., et al. Fibulins: A versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003, 4:479-489.
6. Nakamura T., Lozano P.R., Ikeda Y., et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002, 415:171-175.
7. Schiemann W.P., Blobe G.C., Kalume D.E., et al. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-β and affects protein kinase cascades. J Biol Chem 2002, 277:27367-27377.
8. Wlazlinski A., Engers R., Hoffmann M.J., et al. Down-regulation of several fibulin genes in prostate cancer. Prostate 2007, 67:1770-1780.
9. Albig A.R., Neil J.R., Schiemann W.P. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006, 66:2621-2629.
10. Xie L., Palmsten K., Macdonald B., et al. Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) 2008, 233:155-162.
11. Pos Z., Wiener Z., Pocza P., et al. Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma. Cancer Res 2008, 68:1997-2005.
12. Sobin L.H., Fleming I.D. TNM Classification of Malignant Tumors, 5th edition, 1997. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804.
13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
14. Bissell M.J., Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54.
15. Albig A.R., Schiemann W.P. Fibulin-5 function during tumorigenesis. Future Oncol 2005, 1:23-35.
16. Choi Y.D., Cho N.H., Ahn H.S., et al. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J Urol 2007, 177:1174-1178.
17. Albig A.R., Schiemann W.P. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004, 23:367-379.
18. Watson J.D., Oster S.K., Shago M., et al. Identifying genes regulated in a Myc-dependent manner. J Biol Chem 2002, 277:36921-36930.
19. Yang C.C., Chu K.C., Yeh W.M. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004, 22:1-6.
20. Lipponen P.K. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995, 175:203-210.
21. Lee C., Lee S., Kim D., et al. MP-12.15 The role of transforming growth factor- β1 in human bladder cancer cell lines. Urology 2006, 68. 133.
22. Stetler-Stevenson W.G., Aznavoorian S., Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993, 9:541-573.